Buigues, C.; Navarro-Martínez, R.; Sánchez-Martínez, V.; Serrano-Carrascosa, M.; Rubio-Briones, J.; Cauli, O.
Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen Therapy. Cancers 2020, 12, 1716.
https://doi.org/10.3390/cancers12071716
AMA Style
Buigues C, Navarro-Martínez R, Sánchez-Martínez V, Serrano-Carrascosa M, Rubio-Briones J, Cauli O.
Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen Therapy. Cancers. 2020; 12(7):1716.
https://doi.org/10.3390/cancers12071716
Chicago/Turabian Style
Buigues, Cristina, Rut Navarro-Martínez, Vanessa Sánchez-Martínez, María Serrano-Carrascosa, José Rubio-Briones, and Omar Cauli.
2020. "Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen Therapy" Cancers 12, no. 7: 1716.
https://doi.org/10.3390/cancers12071716
APA Style
Buigues, C., Navarro-Martínez, R., Sánchez-Martínez, V., Serrano-Carrascosa, M., Rubio-Briones, J., & Cauli, O.
(2020). Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen Therapy. Cancers, 12(7), 1716.
https://doi.org/10.3390/cancers12071716
